U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

FDA priority review acceptance for Takeda's Zasocitinib could redefine oral psoriasis treatment.